UBS Group Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by UBS Group from $580.00 to $600.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages also recently issued reports on UTHR. Bank of America boosted their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Wells Fargo & Company increased their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Oppenheimer raised their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Finally, Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $503.90.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $454.00 on Thursday. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $479.50. The firm’s fifty day moving average is $421.07 and its 200-day moving average is $342.41. The firm has a market cap of $19.55 billion, a P/E ratio of 17.20, a P/E/G ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.39 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $437.98, for a total transaction of $1,751,920.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $56,937.40. This represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $450.34, for a total transaction of $4,953,740.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $16,563,955.54. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 408,935 shares of company stock worth $171,884,147. Insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Vanguard Group Inc. increased its holdings in United Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after purchasing an additional 15,312 shares in the last quarter. AQR Capital Management LLC grew its holdings in United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after buying an additional 364,713 shares in the last quarter. Invesco Ltd. raised its position in United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the last quarter. Assetmark Inc. lifted its stake in United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after acquiring an additional 197,384 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after acquiring an additional 4,145 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.